Smith & Nephew SNATS (SNN) recently announced the completion of the first surgery case using its latest CATALYSTEM Primary Hip System. The first surgical procedure using the CATALYSTEM System was completed in the second week of September by three prominent orthopedic surgeons — Dr. Thorsten Seyler of Duke University, Dr. George Haidukewych of Orlando Health, and Dr. Ran Schwarzkopf of NYU Langone Health.The CATALYSTEM Primary Hip System makes use of the exclusive, patent-pending ACCUBROACH Technology, which ...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures – the CATALYSTEM Primary Hip System features a triple-taper stem design with uniform proximal loading.1  The reduced distal stem geometry and shorter lengths are ideal for anterior appro ...

Smith & Nephew SNATS (SNN) recently announced the launch of its TOTAL ANKLE Patient-Matched Guides. These guides are likely to provide surgeons with a predictable and efficient option to plan and perform total ankle replacement procedures.TOTAL ANKLE Patient-Matched Guides are engineered using 3D Systems’ VSP surgical planning workflows and are designed to achieve a precise patient fit using fluoroscopic alignment cues and efficient instrumentation, and provide accuracy to plan.However, shares of SNN lost 0 ...

Portra/E+ via Getty Images It takes time to turn around a large business, particularly when there are enough problems to create a 12-point to-do list, but Smith & Nephew (NYSE:SNN) is delivering on a lot of its targets and the market is taking notice. The shares have climbed over 35% since my last update, beating the broader med-tech sector, as well as peers/rivals like Stryker (SYK), Zimmer Biomet (ZBH), and Enovis (ENOV) with a combination of better than expected revenue and improving margins. It may ...

Smith & Nephew plc (SNN) and InfuSystem Holdings, Inc. (INFU) recently announced a three-year distribution agreement for delivering Smith & Nephew's innovative RENASYS EDGE negative pressure wound therapy (NPWT) system to patients requiring home-based care for chronic wounds. The collaboration aims to enhance patient access to advanced wound care technology, leveraging InfuSystem’s extensive network and service capabilities.Smith & Nephew, a global leader in medical technology, launched the RENASYS EDGE NPW ...

Smith & Nephew SNATS (SNN) recently announced an exclusive digital and advanced analytics collaboration with Healthcare Outcomes Performance Company (HOPCo) – the world’s largest, fully integrated, musculoskeletal value-based care and outcomes management company.The collaboration is likely to enhance solutions for Ambulatory Surgical Center’s (ASC) customers, physicians, and patients through HOPCo’s digital health and analytics platforms, myrecovery and Vitals.More on the PartnershipSmith & Nephew is lookin ...

财务数据和关键指标变化 - 收入为14亿美元,同比增长5.6%,其中汇率因素对收入产生100个基点的负面影响 [14] - 毛利率为70.1%,同比增加30个基点 [28] - 经营利润率为16.7%,同比增加140个基点,达到上限指引范围 [28][29] - 经调整每股收益增长8%至0.376美元 [31] - 经营活动现金流为2.84亿美元,现金转换率为60%,大幅好于去年同期的26% [32][33] 各条业务线数据和关键指标变化 骨科 - 全球膝关节和髋关节分别增长2.1%和4% [16] - 美国骨科收入仍落后,但有积极迹象 [17] - 其他骨科(机器人等)增长17.8% [18] - 创伤和四肢骨科增长11.8%,贡献了整体骨科一半的增长 [19] 运动医疗和耳鼻喉 - 整体增长7.6%,其中关节修复增长6%,剔除中国影响后增长11.8% [20] - 关节修复和REGENETEN是主要贡献者 [20] - 关节镜辅助技术增长8.7% [22] - 耳鼻喉业务增长11.6% [22] 高级伤口护理 - 整体增长3.3%,生物活性和伤口护理产品均有所恢复 [23][24] - SANTYL和GRAFIX的表现有所不同 [24] - 负压伤口护理产品PICO增长8% [25] 各个市场数据和关键指标变化 - 美国市场增长3.6%,其他成熟市场增长6.9%,新兴市场增长9.5% [15] - 国际市场(美国以外)骨科业务增长较快 [16] 公司战略和发展方向及行业竞争 - 公司认为自身拥有良好的基础业务和技术,但过去存在执行和文化方面的挑战 [7][61] - 公司制定了12项计划来解决这些问题,取得了显著进展 [61][62] - 12项计划的关键成就包括:重塑骨科业务、广泛提升生产效率、保持强势业务的良好表现等 [62][63][65] - 公司认为通过12项计划的持续执行,美国骨科业务也有望实现转机 [66][67][70][71] - 公司持续推出创新产品,如CATALYSTEM髋关节系统、CORI机器人系统的新功能等 [73][74] - 公司对未来5%以上的年收入增长和20%以上的利润率目标保持信心 [76][77][78] 管理层对经营环境和未来前景的评论 - 管理层认为市场需求基本恢复到正常水平,不会依赖于强劲的市场环境来完成业绩目标 [195][196][197] 其他重要信息 - 公司将调整报告分部,将更多间接费用分摊至各业务部门,提高成本管理和业务单元的责任 [50][51] - 公司将更加关注资本回报率,并制定了新的资本配置政策 [53][54][55][56] - 公司识别出了额外的125-175百万美元成本节约空间,不需要额外的重组支出 [46][47][48][49] 问答环节重要的提问和回答 问题1 **David Adlington 提问** 是否考虑剥离某些业务部门 [104][105] **Deepak Nath 回答** 公司目前对现有业务组合感到很满意,未来会根据各业务部门的表现和资本回报情况来决定资本配置 [104][105][174][175][176][177] 问题2 **Sebastien Jantet 提问** 各业务部门的资本回报率情况,以及未来是否会披露更多细节 [107][108] **John Rogers 回答** 公司将在年报时披露各业务部门的资本回报率情况,目前骨科业务的回报率低于集团平均水平,但正在改善 [113][114] 问题3 **Richard Felton 提问** CORI机器人在美国市场的渗透率和未来发展前景 [120][121][122][123][124][125][126][127] **Deepak Nath 回答** CORI机器人在美国市场的渗透率已超过公司的整体市场份额,未来将继续通过产品创新和拓展应用场景来提升竞争力和市场份额 [122][123][124][125][126][127]

Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces an exclusive digital and advanced analytics collaboration with Healthcare Outcomes Performance Company (HOPCo) – the world's largest, fully-integrated, musculoskeletal (MSK) value-based care and outcomes management company. This collaboration will focus on enhancing solutions for ASC customers, physicians, and their patients through HOPCo's digital health and analytics platforms, myrecovery® and Vitals® The partnership ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis ...

Smith & Nephew SNATS (SNN) recently announced the receipt of FDA 510(k) clearance for its new CATALYSTEM Primary Hip System. The system is made to meet the changing needs of primary hip surgery, such as the growing popularity of anterior approach procedures and the growing significance of ambulatory surgery centers.Additionally, the CATALYSTEM Primary Hip System makes use of the exclusive, patent-pending ACCUBROACH Technology, which offers demonstrated reproducibility between the broach and implant, ensurin ...